Ann: BrainChip Evaluates Redomiciling to US, page-376

One of the reasons given by the Chair of Brainchip for considering the move to a US Registry and removal from the ASX was apparent difficulties with making announcements on the ASX. I have an expressed position which is different to Brainchip on what they can or cannot announce however just now the following post concerning this very issue appeared on the IMU threads which appears to support Brainchip's argument. This post may or may not be correct however the poster Steini has been around for a very long time on HC so I personally expect it is factual.
My opinion only DYOR
Fact Finder

"Look what happened to CHM last week;

Here the anns on LinkedIn which is aworld first


CHM CDH17 Phase 1/2 Trial Update

Chimeric Therapeutics is pleased to provide an update on progress of its CHM CDH17 Phase 1/2 clinical trial to date. Of the three patients dosed at the first dose level of 50 million cells, two patients have achieved Stable Disease, whereby the cancer is neither increasing nor decreasing in extent or severity, with the tumours remaining at approximately the same size with no new tumours appearing. Interestingly, evidence of immune activation of CHM CDH17 CAR-T cells was observed with exceptional expansion and persistence beyond 28 days. Clinical evidence of tumour necrosis was observed, however additional results are required to determine the outcome.

And then that happened, refused by the ASX to be released

Thank you for your enquiry.

The disclosure you refer to was determined following consultation with our professional advisers and the ASX.

The information published on LinkedIn was not considered to be sufficiently ‘market sensitive’ to justify being released on ASX as a standalone announcement.The Company was reminded of provisions in the ASX Listing Rule Guidance Notes deterring companies from lodging non-market sensitive announcements on ASX.

As the information was determined not to be market sensitive from an ASX perspective, and unable to be released on ASX in a standalone announcement, the Companyshared the information on social media and a standard media release.

Thank you for your interest and ongoing support of Chimeric.

Regards

Most likely IMU's ann attempt got shut down as well.

Steini

13,391 Posts.

4079

02/03/25

14:00

Post #:78098058

Originally posted by rolly777:↑

Look what happened to CHM last week;

Here the anns on LinkedIn which is aworld first


CHM CDH17 Phase 1/2 Trial Update

Chimeric Therapeutics is pleased to provide an update on progress of its CHM CDH17 Phase 1/2 clinical trial to date. Of the three patients dosed at the first dose level of 50 million cells, two patients have achieved Stable Disease, whereby the cancer is neither increasing nor decreasing in extent or severity, with the tumours remaining at approximately the same size with no new tumours appearing. Interestingly, evidence of immune activation of CHM CDH17 CAR-T cells was observed with exceptional expansion and persistence beyond 28 days. Clinical evidence of tumour necrosis was observed, however additional results are required to determine the outcome.

And then that happened, refused by the ASX to be released

Thank you for your enquiry.

The disclosure you refer to was determined following consultation with our professional advisers and the ASX.

The information published on LinkedIn was not considered to be sufficiently ‘market sensitive’ to justify being released on ASX as a standalone announcement.The Company was reminded of provisions in the ASX Listing Rule Guidance Notes deterring companies from lodging non-market sensitive announcements on ASX.

As the information was determined not to be market sensitive from an ASX perspective, and unable to be released on ASX in a standalone announcement, the Companyshared the information on social media and a standard media release.

Thank you for your interest and ongoing support of Chimeric.

Regards

Most likely IMU's ann attempt got shut down as well.

Anyway, have to agree with all posters that it seemed LC presented a bit differently, especiallythe 50 trial participants examplemakes the current trial design more understandable - Mason14, you had some problems with participant numbers, maybe that helps a bit.

For anyone listening first time it sounds a screaming buy, so why are pharma and funds still ignoring IMU and CHM?

Tomorrow Hopper will reveal the Ts & Cs for the latest cap raising on the back of the, what the CHM-sh think, fantastic first CDH17 gastric CAR-T update at lowest dose in an ultra short time frame. Will he finally demand a premium or will he "stab" his CEO in the back again, especially after she secured a AUD4m grant.

Whatever unfolds at CHM tomorrow will be anindication for IMUs future funding choicesas well.